By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Activate Immunotherapy (Formerly Known As NovaRx) 

6828 Nancy Ridge Drive, Suite 100

San Diego  California  92121  U.S.A.
Phone: 858-552-8600 Fax: 858-638-0882


SEARCH JOBS

Activate Immunotherapy has evolved from almost twenty years of research, over $90 million of private funding, and several multi-national clinical studies. Originally founded in 1997 to commercialize the award-winning research of Dr. Habib Fakhrai and associates at the Sidney Kimmel Cancer Center in San Diego and at UCLA, Activate Immunotherapy has never wavered in its passion for utilizing the body's own extraordinarily powerful immune system to fight cancer, fundamentally change the course of the disease, and meaningfully extend and improve patient lives.

Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells.

YEAR FOUNDED:

1997

LEADERSHIP:

Founders: Habib Fakrai and Emmet O’Neal III

CSO: Habib Fakhrai

CEO: Justin Murdock

COO: Todd M. Binder

CBO: Stella M. Sung, Ph.D.

CFO: Robert Davis


Key Statistics


Email: novarx@novarx.com
Ownership: Private

Web Site: NovaRx
Employees:
Symbol: 
 









Company News
Amid Multi-Million Financing and Expanding Exec Management, SoCal's NovaRx Changes Company Name 8/15/2016 7:53:10 AM
Letter Of Intent To Acquire NovaRx Corporation Expires; Viropro Inc. (VPRO) Appoints New Slate Of Officers 5/2/2016 7:41:53 AM
Viropro Inc. (VPRO) Announces Signing Of Letter Of Intent To Acquire Viropro Inc. (VPRO) 10/23/2015 7:47:06 AM
NovaRx Corporation Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Maintenance Therapy in Non-small Cell Lung Cancer to be Presented at ESMO. 9/26/2013 10:08:46 AM
NovaRx Corporation Announces Results of Lucanix® Phase III Therapeutic Vaccine Trial for Post-frontline Maintenance Therapy in Non-small Cell Lung Cancer to be Presented at ESMO 9/25/2013 10:09:18 AM
NovaRx Corporation Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer 6/20/2012 10:39:46 AM
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer 11/4/2009 7:57:04 AM
NovaRx Corporation Appoints Industry Veteran as President and COO 12/4/2008 9:47:11 AM
NovaRx Corporation Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients 8/21/2008 7:30:17 AM
NovaRx Corporation Selects Image Solutions, Inc. (ISI)'s eCTDXPress and ISIWriter 5/1/2008 8:42:33 AM
12
//-->